Open AccessSerum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein expression predicts disease severity in chronic hepatitis C patients
Author(s) -
Huang ChingI,
Huang ChungFeng,
Yeh MingLun,
Lin YiHung,
Liang PoCheng,
Hsieh MengHsuan,
Dai ChiaYen,
Hsieh MingYen,
Lin ZuYau,
Chen ShinnCherng,
Huang JeeFu,
Yu MingLung,
Chuang WanLong
Publication year - 2017
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/j.kjms.2017.05.017
Subject(s) - medicine , gastroenterology , confidence interval , odds ratio , liver biopsy , fibrosis , biomarker , alanine aminotransferase , alanine transaminase , biopsy , pathology , biology , biochemistry
Wisteria floribunda agglutinin‐positive Mac‐2 binding protein (WFA + ‐M2BP) has recently been developed as a promising liver fibrosis glyco biomarker. We assessed its efficacy in evaluating liver disease severity in chronic hepatitis C (CHC) in Taiwan. The association between WFA + ‐M2BP and histological features was evaluated among those CHC patients underwent liver biopsy. We also aimed to clarify the factors determining the performance of WFA + ‐M2BP in CHC. A total of 229 CHC patients were consecutively recruited. The mean value of WFA + ‐M2BP in patients from F0 to F4 was 1.68, 2.23, 3.45, 3.48, 3.77 respectively (linear trend P = 0.008). Linear regression analysis revealed that alanine aminotransferase (odds ratio [OR]: 0.03, 95% confidence intervals [CI]: 0.02–0.05, P < 0.001), AST (OR: −0.1, 95% CI: −0.02 to −0.01, P < 0.001), and liver fibrosis (OR: 0.30, 95% CI: 0.01–0.59, P = 0.043) were the independent factors correlated to serum WFA + ‐M2BP level. The optimal cutoff values of WFA + ‐M2BP for fibrosis stages F1, F2, F3, and F4 were 1.42, 1.61, 1.42, and 2.67, respectively. Multivariate analysis revealed that the platelet count (OR/CI: −0.009/0.986–0.996, P = <0.001), r‐ glutamyl transferase (OR/CI: 0.007/1.000–1.013, P = 0.036), and WFA + ‐M2BP (OR/CI: 0.187/1.057–1.374, P = 0.005). We concluded that WFA + ‐M2BP is a competent noninvasive marker for liver fibrosis assessment in CHC patients.